MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Comprehensive genomic profiles of small cell lung cancer
Comprehensive genomic profiles of small cell lung cancer
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comprehensive genomic profiles of small cell lung cancer
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Comprehensive genomic profiles of small cell lung cancer
Comprehensive genomic profiles of small cell lung cancer

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Comprehensive genomic profiles of small cell lung cancer
Comprehensive genomic profiles of small cell lung cancer
Journal Article

Comprehensive genomic profiles of small cell lung cancer

Tho
2015
Request Book From Autostore and Choose the Collection Method
Overview
We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest human cancers. In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1, sometimes by complex genomic rearrangements. Two tumours with wild-type RB1 had evidence of chromothripsis leading to overexpression of cyclin D1 (encoded by the CCND1 gene), revealing an alternative mechanism of Rb1 deregulation. Thus, loss of the tumour suppressors TP53 and RB1 is obligatory in SCLC. We discovered somatic genomic rearrangements of TP73 that create an oncogenic version of this gene, TP73Δex2/3 . In rare cases, SCLC tumours exhibited kinase gene mutations, providing a possible therapeutic opportunity for individual patients. Finally, we observed inactivating mutations in NOTCH family genes in 25% of human SCLC. Accordingly, activation of Notch signalling in a pre-clinical SCLC mouse model strikingly reduced the number of tumours and extended the survival of the mutant mice. Furthermore, neuroendocrine gene expression was abrogated by Notch activity in SCLC cells. This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer. Genomic sequencing of 110 human small cell lung cancers identifies genomic signatures including nearly ubiquitous bi-allelic inactivation of TP53 and RB1 , a role for NOTCH family genes, and somatic rearrangements that create an oncogenic version of TP73 . Genetic causes of small cell lung cancer Whole-genome sequencing of 110 small cell lung cancers reveals a characteristic bi-allelic inactivation of the tumour suppressor genes TP53 and RB1 in almost all cases. In the only two specimens with no alterations in TP53 and RB1 , chromothripsis activates cyclin D1, leading to the same molecular effect. In addition, 25% of tumours carry inactivating mutations in NOTCH family genes, and the authors show that activation of Notch signalling in a pre-clinical mouse model reduces the number of tumours and extends the survival of the mutant mice. This work highlights possible drug targets in one of the deadliest of human cancers.